TuHURA Biosciences (NASDAQ:HURA) Stock Rating Lowered by Wall Street Zen
by Doug Wharley · The Cerbat GemTuHURA Biosciences (NASDAQ:HURA – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.
HURA has been the subject of several other reports. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Finally, Rodman & Renshaw assumed coverage on TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, TuHURA Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.
View Our Latest Stock Report on HURA
TuHURA Biosciences Stock Performance
Shares of HURA opened at $2.35 on Friday. The stock has a fifty day moving average price of $1.90 and a two-hundred day moving average price of $1.61. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $4.20. The company has a market cap of $149.41 million, a price-to-earnings ratio of -3.73 and a beta of -0.32.
TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, research analysts predict that TuHURA Biosciences will post -0.45 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in TuHURA Biosciences during the third quarter worth about $26,000. JPMorgan Chase & Co. bought a new position in TuHURA Biosciences during the second quarter worth about $27,000. Invesco Ltd. bought a new position in TuHURA Biosciences during the second quarter worth about $30,000. State Street Corp lifted its holdings in TuHURA Biosciences by 4.9% during the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after acquiring an additional 13,594 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in TuHURA Biosciences during the second quarter worth about $31,000. 0.62% of the stock is currently owned by institutional investors.
About TuHURA Biosciences
TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.
At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.